In the light of our results, securin may prove to be a valuable prognostic factor for clinical pathology, although the present data do not yet allow for testing of the possible prognostic value of securin in relation to the gold standard of breast cancer prognostics, the Nottingham Prognostic Index (Elston and Ellis, 1991). The gene discussed is PTTG1; the disease is breast carcinoma.